5 news items
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
ALGS
25 Apr 24
risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
ALGS
5 Mar 24
materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties
- Prev
- 1
- Next